Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.2.1.17 (
lysozyme
)
21,489
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Lysozyme, present in several connective tissues, is synthesized in cartilage by chondrocytes and immediately secreted into the extracellular matrix, where it is bound in the territorial (lacunar) matrix and along collagen fibers. In the epiphyseal growth plate,
lysozyme
levels increase toward the cartilage-bone junction, but cartilage
lysozyme
seems to be bound or inactivated by an inhibitor.
Parathyroid
extract injections decrease bone
lysozyme
levels. Cartilage
lysozyme
levels are low in rickets, while vitamin D increases it in both cartilage and aorta, suggesting an association between
lysozyme
and the calcification process. Although it is cationic and forms salt-like complexes with cartilage proteoglycans and chondroitin sulfate in vitro,
lysozyme
does not seem to be bound to proteoglycans in the native tissue. Proteoglycans in cartilage exist in a monomeric and aggregated form. Aggregation occurs by an interaction of monomers with hyaluronic acid and spedific link proteins. Aggregated proteoglycans inhibit mineral accretion in vitro. Mammalian cartilage
lysozyme
but not hen egg white
lysozyme
seems to inactivate this inhibitory capacity of aggregated proteoglycans, which is probably due to an interaction with hyaluronic acid resulting in a disaggregation. Therefore, we hypothesize that cartilage
lysozyme
plays an important role in the regulation and initiation of cartilage calcification.
...
PMID:Lysozyme in calcifying tissues. 119 45